HEALEY ALS Platform Trial Webinar: February 26, 2026 | Neurofilament Analysis

Why It Matters

NFL provides a minimally invasive, quantitative tool to predict disease trajectory and gauge drug efficacy, accelerating ALS therapeutic development while improving patient stratification.

Key Takeaways

• Neurofilament light chain (NFL) measurable in blood predicts ALS progression.
• Baseline NFL levels correlate with faster functional decline in placebo groups.
• NFL remains stable over six months for ~95% of patients, minor fluctuations.
• Significant NFL reductions observed in SOD1‑targeted therapy, indicating pharmacodynamic effect.
• Small subset shows >40% NFL spikes, highlighting variability considerations in trials.

Summary

The Healey ALS Platform Trial webinar focused on neurofilament light chain (NFL) as a biomarker in amyotrophic lateral sclerosis. Clinician‑researcher Dr. James Barry and biostatistician Jenny Wing explained NFL’s biology, its detection in cerebrospinal fluid and blood, and why it is gaining prominence in ALS drug development.

Key insights included NFL’s role as a prognostic marker: higher baseline levels predict steeper declines in ALS Functional Rating Scale scores, while lower levels associate with slower progression and longer survival. Because blood NFL correlates tightly with CSF concentrations, it offers a less invasive alternative for patient monitoring. The webinar also highlighted NFL’s utility as a pharmacodynamic read‑out, citing the tofersen trial where treated participants showed a >50% reduction in NFL alongside clinical slowing, confirming target engagement.

Notable examples featured a graph demonstrating the strong CSF‑blood correlation and Jenny Wing’s analysis of the Healey platform’s placebo arm. Her data showed that 95% of participants exhibited <±12% NFL variation over six months, whereas a small 5% subgroup displayed fluctuations up to +40% or –29%, underscoring the need to account for outliers in trial designs.

The implications are clear: NFL can streamline ALS trial enrollment, reduce reliance on lumbar punctures, and serve as an early indicator of therapeutic effect. However, trial protocols must incorporate strategies to manage the modest variability observed in a minority of patients, ensuring robust interpretation of treatment outcomes.

Original Description

James Berry, MD, MPH, and biostatistician Jenny Wang, MS, PhD, of Massachusetts General Hospital led a discussion titled “Understanding Neurofilament (NfL) in ALS: What it tells us and how it is used in clinical trials”. The presenters looked at NfL as a prognostic biomarker and dynamic trial endpoint in ALS research, citing real-world examples such as NfL analyses conducted using data from the HEALEY ALS Platform Trial.

Visit the Mass General website to register for future Platform Trial webinars: https://www.massgeneral.org/neurology/als/research/platform-trial-news

Sign up for the ALS Link to stay up to date about news and research from the Sean M. Healey & AMG Center for ALS: https://lp.constantcontactpages.com/sl/wQfOqgA/ALSLink

Follow MGH Neurology on Facebook (https://www.facebook.com/MGHNeurology/) and X (https://x.com/MGHNeurology)